Skip to main content
. 2020 Aug 15;9(1):1806009. doi: 10.1080/2162402X.2020.1806009

Figure 4.

Figure 4.

EpCAM CAR-T-mediated CRS is tumor independent.

(a) Serum levels of mouse IL-6 at day 3 following CAR-T cell transfer (BALB/c mice: CAR-T+tumor vs CAR-T, ns; CAR-T+tumor vs Con T+tumor, ns; CAR-T vs Con T+tumor, ***p=.0005. C57BL/6J mice: CAR-T+tumor vs CAR-T, ns; CAR-T+tumor vs Con T+tumor, *p=.0386; CAR-T vs Con T+tumor, **p=.0017).(b) Serum level of mouse IFN-γ at day 3 following CAR-T cell transfer. (BALB/c mice: CAR-T+tumor vs CAR-T, ns; CAR-T+tumor vs Con T+tumor, *p=.0215; CAR-T vs Con T+tumor, ***p=.0006. C57BL/6J mice: CAR-T+tumor vs CAR-T, ns; CAR-T+tumor vs Con T+tumor, *p=.0155; CAR-T vs Con T+tumor, *p=.0370).BALB/c mice n=5 per group; C57BL/6J mice, CAR-T with tumor (CAR-T+tumor) and CAR-T without tumor (CAR-T), n=7, control T cells with tumor (Con T+tumor), n=6. A two-tailed unpaired two-sample t-test was used for statistical analysis. All data are presented as the mean ± SD; ns, not significant.